applications

Pulmatrix believes it has developed a novel approach for the treatment and prevention of infectious disease which can transform the landscape of poorly addressed infectious and progressive respiratory diseases including rhinovirus, influenza, and chronic pulmonary diseases.

The demonstrated broad-spectrum efficacy and strong safety profile of Pulmatrix therapies could allow them to be administered as treatment or preventative measures, in high risk settings, or as a first-line of defense to respond to traditional and emerging infectious agents. Further, Pulmatrix drugs have potential for use as chronic maintenance therapies in patients with underlying pulmonary disease, and in other indications where prophylactic intervention may mitigate serious clinical consequences of infection.

Pulmatrix programs offer the following advantages over current recommended strategies to address infectious and progressive respiratory disorders:

• Efficacy as a “one-drug, multiple-bug” technology to treat, prevent, and reduce transmission of a broad spectrum of airborne pathogens that pose community and public health risks;
• Demonstrated clear safety and tolerability profile;
• A unique mechanism of action that should not be susceptible to conventional pathogen resistance as observed with other prophylactic and therapeutic countermeasures.br

Based on the unique attributes of Pulmatrix’s drugs which harness the inherent biophysical properties and host defenses of the airway to safely treat, prevent, and inhibit the spread of airborne infections independent of pathogen, the Company is developing a deep and broad pipeline focused on a range of respiratory diseases, which have considerable unmet medical need.

To date, the Company has built an impressive package of pre-clinical data demonstrating treatment efficacy, prophylaxis, and transmission control in multiple animal species, in both viral and bacterial diseases. The Company’s lead drug candidate has demonstrated an excellent safety profile in a multi-species toxicology study and Phase I human trial conducted in 2008.